Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Claims 1-16 (Canceled).

17. (Previously presented) A hybrid fragment of tetanus toxin comprising a fragment C and a fragment B or a fraction of fragment B having at least 11 amino acid residues, wherein the hybrid fragment is capable of transferring *in vivo* a protein, a peptide, or a polynucleotide through a neuromuscular junction and at least one synapse.

18. (Previously presented) A hybrid fragment of tetanus toxin comprising a fragment C and a fragment B or a fraction of fragment B having at least 11 amino acid residues and a fraction of a fragment A devoid of its toxic activity corresponding to the proteolytic domain having a zinc-binding motif located in the central part of the chain between amino acids 225 and 245, wherein the hybrid fragment is capable of transferring *in vivo* a protein, a peptide or a polynucleotide through a neuromuscular junction and at least one synapse.

Claims 19-20 (Canceled)

21. (Previously presented) A composition containing an active molecule in association with a hybrid fragment of tetanus toxin according to claim 17.

22. (Original) The composition according to claim 21, wherein the active molecule is selected from the group consisting of protein SMN, BDNF (brain-derived

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

neurotrophic factor), NT-3, NT-4/5, GDNF (Glial cell-line derived neurotrophic factor), IGF (Insulin-like growth factor), PNI (protease nexin I), SP13 (Serine Protease Inhibitor protein), ICE , Bcl-2, GFP (green fluorescent protein), endonucleases like I-SceI or CRE, antibodies or drugs specifically directed against neorodengenerative diseases such as latero spinal amyotrophy (LSA).

23. (Previously presented) The composition according to claim 21, wherein the active molecule is a polynucleotide encoding a protein.

Claims 24-33 (Canceled).

34. (Previously presented) The composition according to claim 23, wherein the polynucleotide further comprises a promoter capable of expression in neurons.

35. (Previously presented) The composition according to claim 34, wherein the polynucleotide further comprises an enhancer.

36. (New) The hybrid fragment of tetanus toxin according to claim 17, comprising a fragment C and a fraction of fragment B having at least 11 amino acid residues.

37. (New) The hybrid fragment of tetanus toxin according to claim 36, wherein the fraction of fragment B consists of 11 amino acid residues.

38. (New) The hybrid fragment of tetanus toxin according to claim 18, comprising a fragment C, a fraction of fragment B having at least 11 amino acid residues, and a fraction of a fragment A devoid of its toxic activity corresponding to the

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

proteolytic domain having a zinc-binding motif located in the central part of the chain between amino acids 225 and 245.

39. (New) The hybrid fragment of tetanus toxin according to claim 38, wherein the fraction of fragment B consists of 11 amino acid residues.

40. (New) A composition comprising an active molecule in association with a hybrid fragment of tetanus toxin according to claim 36 or 37.

41. (New) The composition according to claim 40, wherein the active molecule is selected from the group consisting of protein SMN, BDNF (brain-derived neurotrophic factor), NT-3, NT-4/5, GDNF (Glial cell-line derived neurotrophic factor), IGF (Insulin-like growth factor), PNI (protease nexin I), SP13 (Serine Protease Inhibitor protein), ICE , Bcl-2, GFP (green fluorescent protein), endonucleases like I-SceI or CRE, antibodies or drugs specifically directed against neorodengenerative diseases such as latero spinal amyotrophy (LSA).

42. (New) The composition according to claim 40, wherein the active molecule is a polynucleotide encoding a protein.

43. (New) The composition according to claim 40, wherein the active molecule is a polypeptide.

44. (New) The composition according to claim 42, wherein the polynucleotide further comprises a promoter capable of expression in neurons.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com